Research programme: HIV protease inhibitors - TaiMed Biologics
Alternative Names: P-1946Latest Information Update: 04 Nov 2017
At a glance
- Originator Ambrilia Biopharma
- Developer TaiMed Biologics
- Class
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-1-infections in Taiwan (IM, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-1-infections in Taiwan (SC, Injection)
- 09 Oct 2015 Preclinical development is ongoing in Taiwan